In a new job - September 8, 2017
New Head of respiratory, inflammation and autoimmunity at AstraZeneca
AstraZeneca’s Innovative Medicines and EarlyDevelopment (IMED) Biotech Unit has appointed Professor Maria Belvisi as Vice President and Head of Respiratory, Inflammation and Autoimmunity (RIA). She will start her new position immediately and will have responsibility for implementing the company’s respiratory research strategy focused on the three key areas of lung epithelium, lung immunity and lung regeneration, through […]
In a new job - September 5, 2017
New Vice President at NeuroVive
NeuroVive Pharmaceutical has appointed Mark Farmery as Vice President Business Development. Dr Farmery will report to CEO Erik Kinnman and will join the company’s management team. The appointment strengthens and expands the team in a critical area and is in line with NeuroVive’s dual business model, which focuses on early phase projects for out-licensing at […]
In a new job - September 4, 2017
New CEO of Symcel
Symcel Sweden has announced the appointment of Jesper Ericsson as new Chief Executive Officer – succeeding Christer Wallin who is now retiring. ”I very much look forward to developing the plan and globally establishing Symcel’s solutions for phenotypic screening – with a substantial focus on sales and marketing in the coming years,” said Jesper Ericsson. Jesper […]
In a new job - August 21, 2017
New Vice President at NDA Advisory Board
Werner Van den Eynde, MD, a specialist physician in pharmaceutical medicine, has joined NDA Group to head-up the NDA Advisory Board. Dr. Van den Eynde has extensive international pharmaceutical experience, holding senior positions within Chemo – Exeltis, GE Healthcare, Abbott and Solvay Pharmaceuticals. As Vice President of NDA Advisory Services Ltd, Dr. Van den Eynde […]
In a new job - August 4, 2017
Changes to the Board of Directors at Dignitana
Dignitana announces that Board Member Magnus Nilsson will resign from his position due to changes in his current professional responsibilities. As CEO of Xvivo Perfusion AB, Magnus Nilsson will move to the United States to develop Xvivo’s U.S. subsidiary during the coming period. Thereby he will spend most of his time abroad. Magnus Nilsson has […]
In a new job - August 4, 2017
New CEO of OxThera
OxThera has appointed Matthew Gantz as their new CEO. He succeeds Elisabeth Lindner as CEO, who will continue as COO of Oxthera overseeing the Oxabact program. OxThera is developing a novel treatment, Oxabact, for Primary hyperoxaluria (PH), a fatal disease in children, and where there are currently no available therapies. The company is poised to initiate a pivotal […]
